Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
New blood biomarker data from Eli Lilly, Roche and Alamar Biosciences headline a London conference where non-amyloid mechanisms …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
A single dose of the lysergide orally disintegrating tablet achieved statistically significant MADRS improvement at six weeks compared …
Amtagvi becomes the first tumour-infiltrating lymphocyte therapy approved in Australia for advanced melanoma, entering a market with the …
June’s pharmaceutical headlines reflect significant regulatory shifts, industry reorganization, and technological innovation shaping healthcare policy and drug development.
Landmark ASCO results and advances in liquid biopsy-driven treatment switching spotlight innovation in cancer research and personalized medicine.
Novavax’s protein-based COVID-19 vaccine, Nuvaxovid, wins FDA approval for older adults and people with underlying health risks under …
Already a subscriber? Log in